Pfizer to buy RSV drug ReViral for up to $525m

NEW YORK, Apr 07 (Reuters): Pfizer Inc said on Thursday it would buy privately-held ReViral Ltd in a deal worth as much as $525 million, including milestone payments, to gain access to experimental drugs against the respiratory syncytial virus (RSV).

London-based Reviral has four RSV therapies in its pipeline, with two currently in mid-stage studies, including its lead product candidate sisunatovir.

The deal marks the US drugmaker's second acquisition in less than six months to enhance its drug portfolio. Pfizer acquired Arena Pharmaceuticals in a deal worth $6.7 billion in December.